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HEMATOPOIESIS
An RNAinterference model of RPS19 deﬁciency in Diamond-Blackfan anemia
recapitulates defective hematopoiesis and rescue by dexamethasone: identiﬁcation
of dexamethasone-responsive genes by microarray
Benjamin L. Ebert, Michele M. Lee, Jennifer L. Pretz, Aravind Subramanian, Raymond Mak, Todd R. Golub, and ColinA. Sieff
Diamond-Blackfan anemia (DBA), a con-
genitalerythroblastopenia,isamodeldis-
ease for the study of erythroid differentia-
tion but is poorly understood. RPS19 is
the only gene yet to have been associated
with DBA, but its relevance to erythroid
differentiation is unclear. The molecular
basis for the stimulation of erythropoi-
esis by glucocorticoids in patients with
DBA has not been identiﬁed. We demon-
strate that targeted degradation of the
RPS19 transcript, through retroviral ex-
pression of short hairpin RNAs (shRNAs),
blocks the proliferation and differentia-
tion of erythroid progenitor cells in cul-
tured human CD34 cells. Treatment of
RPS19-deﬁcient cells with dexametha-
sone restores erythroid differentiation to
normal levels. We investigated the mo-
lecular basis of pharmacologic therapies
for DBA using oligonucleotide microar-
rays to survey gene expression in CD34
cells treated with combinations of dexa-
methasone, erythropoietin, stem cell fac-
tor,andinterleukin-3.Dexamethasonedid
not alter expression of RPS19 but acti-
vated a genetic program that includes a
setofkeyhematopoieticregulatorygenes.
Genes speciﬁc to erythroid progenitor
cells were up-regulated by dexametha-
sone, while genes speciﬁc to noneryth-
roid lineages were down-regulated. Deﬁ-
ciency of RPS19 therefore blocks
proliferation of immature erythroid pro-
genitor cells, and dexamethasone acti-
vates proliferation of the same cell popu-
lation through mechanisms independent
of RPS19. (Blood. 2005;105:4620-4626)
© 2005 by TheAmerican Society of Hematology
Introduction
Diamond-Blackfan anemia (DBA) is a rare congenital anemia
characterized by erythroid hypoplasia, growth retardation, and
other congenital anomalies.1-3 The molecular pathophysiology of
DBA, leading to an almost complete loss of erythroid precursor
cells in the bone marrow, is not understood. Insights into the basis
of DBA promise not only to direct the development of novel
therapeutic strategies for DBA, but also to inform the study of stem
cell commitment and erythroid differentiation.
The only gene that has thus far been associated with DBA
encodes ribosomal protein S19 (RPS19),4 while mutations in at
least 2 other genes are likely to cause the DBA phenotype.5 The
mechanisms whereby mutations in RPS19, a component of the
small ribosomal complex, inhibit erythropoiesis are unknown.
Mutations occur in approximately 25% of patients with DBA.
Large deletions of one allele6-8 and certain frameshift and nonsense
mutations lead to haploinsufﬁciency9 of RPS19. Taken together
with reports that other missense mutations are scattered throughout
the RPS19 gene,6,10,11 these data favor the notion that allelic
insufﬁciency can cause DBA. Mice with homozygous inactivation
of RPS19 are not viable, and although mice with inactivation of one
allele were reported to have a normal hematocrit, RPS19 mRNA
appears to be normal.12 It remains unclear whether partial loss of
RPS19 function, through allelic insufﬁciency, is sufﬁcient to cause
the DBAphenotype.
Glucocorticoids are the primary pharmacologic therapy for
patients with DBA, increasing red blood cell production in more
than 50% of patients and increasing the proliferation of erythroid
progenitor cells in vitro.13,14 However, the basis for the activity of
dexamethasone in erythropoiesis has not been elucidated.
We investigated the effects of decreased RPS19 levels on
erythropoiesis using RNAinterference (RNAi).We targeted RPS19
mRNA transcripts for degradation in normal human hematopoietic
progenitor cells and assayed the resulting changes in erythroid
differentiation in vitro. We used this model system to study the
activity of glucocorticoids in DBA. Furthermore, we used oligonu-
cleotide microarrays to identify molecular targets of dexametha-
sone in primary human hematopoietic progenitor cells.
Materials and methods
Retroviral production and infection
Sequences targeted by short hairpin RNAs (shRNAs) are listed in Figure 1.
shRNAs were cloned into pRETRO-SUPER, a self-inactivating, murine
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4620 BLOOD, 15 JUNE 2005 VOLUME 105, NUMBER 12stem cell virus (MSCV)–derived, puromycin-expressing retroviral vector.15
Vesicular stomatitis virus-G–pseudotyped retrovirus was produced by
cotransfection of retroviral vectors with packaging plasmids into 293
EBNA cells (Invitrogen, Frederick, MD). Primary CD34 cells and HEL
cells were plated one day prior to retroviral infections. Retroviral infections
were performed in the presence of 8 g/mL polybrene. At 24 hours after
infection, retrovirally infected cells were selected using 1 g/mL puromy-
cin (Sigma, St Louis, MO).
The luciferase shRNA, cloned into an identical vector as the test
shRNAs, was used as a control because it does not target any human genes
but decreases expression of an exogenous luciferase gene and therefore
engagestheDicerandRNA-inducedsilencingcomplex(RISC)complexes.16
Culture of primary and transformed cells
Human bone marrow CD34 cells used in RNAi experiments were
obtained from Cambrex (Poietics; Cambrex, East Rutherford, NJ). Ery-
throid differentiation was induced in 2 steps in liquid culture. For the ﬁrst 7
days, cells were cultured in Serum-Free Expansion Medium (SFEM; Stem
Cell Technologies, Vancouver, BC) supplemented with penicillin/
streptomycin, glutamine, 25 ng/mL stem cell factor (SCF), 10 ng/mL
interleukin-3 (IL-3), 10 ng/mL interleukin-6 (IL-6), and 0.5 IU/mL
erythropoietin (Epo).After 7 days, cells were cultured in the same medium
supplemented with 3 IU/mL Epo. Dexamethasone (Sigma) was added
following retroviral infection at a concentration of 1 M. Myeloid
differentiation was induced in SFEM containing 25 ng/mL SCF, 10 ng/mL
IL-3, 40 ng/mL Flt-3 ligand, and 15 ng/mL granulocyte colony-stimulating
factor (G-CSF). SCF, IL-3, and IL-6 were obtained from Stem Cell
Technologies; Flt-3 ligand was obtained from R&D Systems (Minneapolis,
MN); and Epo (epoetin) and G-CSF (ﬁlgrastim) were obtained fromAmgen
(Thousand Oaks, CA).
For oligonucleotide microarray experiments, normal adult bone marrow
was obtained from volunteer donors under a Dana-Farber Cancer Institute
(DFCI) protocol. Mononuclear cells were collected from the interface after
Ficoll Hypaque separation. Lineage-negative cells were collected after
separation on a magnetic bead column (Dynal, Biotech, Brown Deer, WI),
and CD34 cells were puriﬁed by ﬂuorescence-activated cell sorting. One
sample was processed immediately for RNApreparation, and the remaining
aliquots were cultured in the presence of either Epo (2 IU/mL) alone, Epo 
IL-3 (20 ng/mL), or Epo  SCF (50 ng/mL), for 18 or 48 hours. Each
growth factor combination was incubated in the presence or absence of
108 M dexamethasone. We chose this low concentration of dexametha-
sone for the gene expression studies because some DBA patients are
extremely sensitive to very low doses of prednisone and because this
concentration has been shown to be very effective in synergy with SCF
in erythroid expansion studies.17,18 Cells cultured for 10 or 15 days were
cultured in the 2-step erythroid differentiation conditions described in
the previous paragraph.
K562, HEL, and TF-1 cells were obtained from American Tissue
Culture Collection (ATCC, Manassas, VA). K562 and HEL cells were
cultured in RPMI supplemented with 10% fetal bovine serum, penicillin/
streptomycin, and glutamine. TF-1 cells were cultured in identical medium
with the addition of 1 ng/mL granulocyte-macrophage colony-stimulating
factor (GM-CSF, ﬁlgrastim;Amgen).
Real-time RT-PCR
RNA was puriﬁed using Trizol (Life Technologies, Bethesda, MD). cDNA
was produced with the Superscript II reverse transcriptase (Invitrogen)
using oligo(dT) primers. Primers and probes for real time reverse transcrip-
tase–polymerase chain reaction (RT-PCR) were obtained from Applied
BiosystemsAssays: gene expressionAssay ID Hs00357218_g1 for RPS19,
Hs00231112_m1 for GATA1, 401846 for -actin, and Hs00735285 for
RPS14 (Applied Biosystems, Foster City, CA). To calculate shRNA
efﬁcacy, RPS19 mRNA levels in cells expressing an RPS19 shRNA were
compared with RPS19 levels in cells expressing a control shRNA. -Actin
was used as an endogenous control for infections of HELcells. CD34 cells
infected with RPS19 shRNAs had a severe growth defect and expressed
-actin at very low levels, so the RPS14 gene was used as the endogenous
control. Each real-time PCR reaction was performed in triplicate. Each
knockdown experiment was performed at least twice, and the results of
representative experiments are reported.
Western blot analysis
Cells were washed with phosphate-buffered saline and resuspended in lysis
buffer containing 10 mM Tris (tris(hydroxymethyl)aminomethane), 100
mM NaCl, 1 mM EDTA (ethylenediaminetetraacetic acid), 1% triton-X,
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS). Blots
were blocked with 5% nonfat dry milk in Tris-buffered saline plus 0.1%
Tween 20 and probed with a rabbit antibody against RPS199 at a
concentration of 0.50 g/mL and tubulin (Ab-4; Lab Vision, Fremont, CA)
at a concentration of 0.75 g/mL. Binding of horseradish peroxidase–linked
secondary antibodies was visualized using the enhanced chemiluminescence
(ECL) protein detection system (Amersham,Arlington Heights, IL).
Flow cytometry
Cells were harvested for ﬂow cytometry 4 days after retroviral infection, 3
days after selection with puromycin.Approximately 1 to 5  105 cells were
labeledwithaphycoerythrin-conjugatedantibodytoglycophorin-A(Gly-A,
CD235a, Clone GA-R2; BD-Pharmingen, San Diego, CA). Flow cytometry
was performed using a FACScan ﬂow cytometer from Becton Dickinson
(San Jose, CA).
Methylcellulose colony assays
At 3 days after retroviral infection, and 2 days after selection with
puromycin, cultured hematopoietic cells were plated in methylcellulose
containing Epo, SCF, GM-CSF, and IL-3 (H4434; Stem Cell Technologies)
plus 1 g/mL puromycin in 35-mm plates. Colony formation was assessed
after 14 days of culture at 37°C in a humidiﬁed atmosphere with 5% CO2.
Evaluation of the colony assays was performed by an individual blinded to
the experimental conditions. Since the methylcellulose cultures were plated
after CD34 sorting and 5 days in liquid culture, we found that the erythroid
colonies were virtually all mature erythroid burst-forming units (BFU-Es,
small single or multicentric hemoglobinized colonies) at day 14. Similarly,
granulocyte-macrophage colony-forming units (CFU-GMs) were smaller
than obtained from cultures plated on day 0, and therefore granulocyte,
monocyte, and granulocyte-monocyte colonies of more than 10 cells were
scored as positive. Cells processed in parallel that were not retrovirally
infected, but were exposed to puromycin in liquid and methylcellulose
culture, did not produce any colonies.
DNA microarrays
RNAwas prepared using Trizol (Life Technologies) in the presence of 5 g
linear polyacrylamide (GenElute LPA; Sigma) and 100 ng yeast tRNA
(RocheApplied Sciences, Indianapolis, IN). RNAwas linearly ampliﬁed by
2 rounds of in vitro transcription (IVT) by the method of Hunter and
colleagues, modiﬁed to maintain representation of mRNAlevels from small
starting quantities of RNA and avoid template-independent ampliﬁcation
(Baugh et al19).
Brieﬂy, ﬁrst-round ampliﬁcation was carried out with oligo(dT)-T7
primers and Superscript II (Invitrogen) in the presence of the single-
stranded nucleic acid binding protein T4gp32 (USB) for one hour at 4°C.
After second-strand synthesis in the presence of DNA polymerase, Esche-
richia coli RNase H, and E coli DNA ligase (Invitrogen, Cleveland, OH),
the DNA was polished with T4 DNA polymerase and puriﬁed by
phenol/chloroform extraction followed by chromatography on a BioGel P-6
MicroSpin Column (BioRad, Hercules, CA). After precipitation, IVT was
performed (Ribomax kit; Promega), and the IVT products were puriﬁed
using a Qiagen RNeasy Mini Column (Qiagen, Valencia, CA). For
second-round ampliﬁcation, random hexamer primers were added to the
cRNA and RT was carried out at 37°C (20 minutes), 42°C (20 minutes),
50°C (10 minutes), and 55°C (10 minutes), and heat inactivated at 65°C (15
minutes). After RNAse H addition and annealing of oligo(dT)-T7 primer,
second strand was synthesized without E coli ligase.After processing as for
the ﬁrst round, biotin-labeled aRNA was prepared using the Enzo kit
(Affymetrix, Santa Clara, CA). A detailed protocol is described in the
Document S1 (available on the Blood website; see the Supplemental
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for each condition without pooling samples. Details of culture conditions
for each microarray experiment are included in the Supplemental Materials
(TablesS1-S5).ThecRNAwashybridizedtoAffymetrixU133Aoligonucle-
otide microarrays.
Microarray data were analyzed using the GeneCluster2 software package.20
The nearest neighbors of RPS19 and Gly-A, genes that follow a similar
pattern of expression across samples, were identiﬁed using the Pearson
correlation. Genes regulated by dexamethasone were identiﬁed by ranking
them according to their signal-to-noise ratio (SNR).21The complete dataset,
along with supplementary information, is available online (Table S5).
Results
Efﬁcacy of RPS19 shRNA retroviruses
Approximately 25% of patients with DBA have a mutation in one
allele of the gene encoding RPS19, but the functional consequences
of most mutations are unknown, and the role of RPS19 in erythroid
differentiation is not clear. To test whether the level of RPS19
expression is critical for erythroid differentiation, we designed
retroviruses expressing RPS19 shRNAs that target RPS19 mRNA
transcripts for degradation.
We generated 4 shRNAretroviruses that target different regions
of the RPS19 gene (RPS19-R1 to RPS19-R4) and an shRNA
targeting GATA-1, a transcription factor critical for erythroid
differentiation. In order to test the efﬁcacy of each shRNA in a
homogeneous cell population that is not undergoing differentiation,
we infected HELcells, a erythroleukemia cell line, with the shRNA
retroviruses. As shown in Table 1, each shRNA decreased expres-
sion of the RPS19 gene relative to the luciferase shRNAcontrol by
more than 50%. RPS19 shRNAs also decreased expression of the
RPS19 protein as demonstrated by Western blot (Figure 1). The
shRNAs decreased RPS19 expression in CD34 cells as well, by
94%, 86%, and 84%, respectively, for RPS19-R2, RPS19-R3,
and RPS19-R4.
RPS19 shRNAs block erythroid differentiation
The central phenotypic abnormality in patients with DBA is a
deﬁciency of erythroid precursor cells in the bone marrow. We
tested the effects of RPS19 shRNAs on hematopoietic progenitor
and precursor cells using 2 in vitro assays of erythroid differentia-
tion. First, we assayed expression of Gly-A, an erythroid-speciﬁc
cell surface protein, by ﬂow cytometry after induction of erythroid
differentiation in liquid culture. Second, we analyzed the effects of
RPS19 shRNAs on the formation of hematopoietic colonies after
culture in methylcellulose.
The 2-phase induction of erythroid differentiation in liquid
culture results in a synchronized differentiation of primary CD34
cells with gradual up-regulation of Gly-A expression over the
course of the 7-day experiment. As shown in Figure 2A, mean
Gly-A expression did not vary signiﬁcantly between cells infected
with control shRNAs targeting the luciferase gene or cells infected
by the empty vector retrovirus. The GATA1 shRNA, encoding a
transcription factor that is critical for erythroid differentiation,
decreased mean Gly-A expression to 53% plus or minus 6% of the
control. All 4 RPS19 shRNAs decreased mean Gly-A expression,
most powerfully by the RPS19-R1 shRNA, which decreased Gly-A
to 57% plus or minus 13%. When cultured in the presence of
cytokines promoting myeloid differentiation, the induction of
CD11b was mildly decreased by expression of RPS19 shRNAs
(Figure 2B). For each of the RPS19 shRNA retroviruses, the
decrease in GlyA expression was statistically signiﬁcant, with P
less than .01 by a 2-tailed Student t test, while the decrease in
CD11b was not statistically signiﬁcant, with P greater than .10.
Expression of RPS19 shRNAs severely decreased the formation
of all hematopoietic colonies after culture in methylcellulose
(Figure 2C-D). The suppression of both BFU-E colony formation
was statistically signiﬁcant with P less than .001 for each RPS19
shRNA; the statistical signiﬁcance of the decrease in CFU-GM
colony formation was less dramatic, with P equal to .01 for
RPS19-R1, P equal to .02 for RPS19-R2, and P equal to .04 for
RPS19-R4. The decrease in erythroid colony formation was
approximately twice as great as the decrease in myeloid colony
formation. In contrast to RPS19 shRNAs, GATA1 shRNAs de-
creased erythroid colony formation but did not decrease the
number of CFU-GM colonies (Figure S1).
Differentiation and proliferation are intimately linked in eryth-
ropoiesis. The effects of RPS19 shRNAs on Gly-A expression and
hematopoietic colony formation could be caused by impaired
proliferation of erythroid progenitor cells. To assess proliferation
independent of differentiation, we expressed RPS19 shRNAs in
transformed cell lines. As shown in Figure 3, RPS19 shRNAs
impaired the proliferation of CD34 cells, 3 hematopoietic cell
lines (HEL, K562, and TF-1), as well as 293 cells, an embryonic
kidney cell line. The dramatic decrease in methylcellulose colony
formation by RPS19-deﬁcient cells may be due, at least in part,
to a severe proliferative defect that prevents the formation of
mature colonies.
Dexamethasone rescues erythroid differentiation in
RPS19-deﬁcient cells
Dexamethasone is the most effective pharmacologic therapy for
patients with DBA. We investigated whether dexamethasone could
correct the functional defect in erythroid differentiation caused by
RPS19 shRNAexpression in primary human hematopoietic cells.
Dexamethasone was added to the liquid culture medium after
infection of CD34 cells with shRNA retroviruses. While mean
Gly-AexpressionwasdecreasedincellsexpressingRPS19shRNAs,
treatment with dexamethasone increased mean Gly-Aexpression to
a similar degree, 2.0- to 3.5-fold, in cells expressing the luciferase
shRNA control and each of the RPS19 shRNAs (Figure 4A). The
increase in Gly-A expression in cells treated with dexamethasone
was sufﬁcient to correct the decrease in Gly-A expression associ-
ated with each RPS19 shRNA. The effects of dexamethasone were
independent of RPS19 expression, as Gly-A levels increased to a
similar extent in control cells and in cells expressing each of the
RPS19 shRNAs.
Figure 1. shRNA retroviruses decrease expression of RPS19. The effect of
RPS19 shRNAretroviruses on RPS19 protein levels was evaluated by Western blot.
Table 1. Percentage knockdown in transcript levels in HEL cells
infected with RPS19 and GATA-1 shRNA retroviruses
Name Targeted sequence % knockdown
Luciferase CTTACGCTGAGTACTTCGA NA
RPS19-R1 AAGAGCTTGCTCCCTACGA 75
RPS19-R2 ACTGACACCTCAGGGACAA 77
RPS19-R3 CTGGTTCTACACGCGAGCT 59
RPS19-R4 GCACAAAGAGCTTGCTCCC 61
GATA-1 GCGCCTGATTGTCAGTAAA 67
NAindicates not applicable.
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increased erythroid colony formation both in cells infected with the
control shRNA and in cells infected with each RPS19 shRNA (Figure
4B). Dexamethasone increased the formation of BFU-E colonies to a
greater extent than CFU-GM colonies (Figure 4C). For cells express-
ing the luciferase, RPS19-R2, and RPS19-R4 shRNAs, the relative
increase in BFU-E compared with CFU-GM colony formation was
statistically signiﬁcant (P  .05 by 2-tailed Student t test).
Dexamethasone is known to increase the proliferation of immature
erythroid progenitor cells in vitro.17 To study the role of dexametha-
sone in RPS19 deﬁciency independent of the activity of glucocorti-
coids on primary erythroid progenitor cells, we examined the
proliferation of HELcells expressing RPS19 shRNAs.As shown in
Figure 4D, dexamethasone did not inﬂuence the proliferation of
cells expressing the luciferase control shRNA. RPS19 shRNAs
decreased the proliferation rate of HEL cells, but dexamethasone
did not increase the growth rate, indicating that RPS19 activity was
not increased by dexamethasone in RPS19-deﬁcient HELcells.
Effect of DBA treatment modalities on gene expression
Having demonstrated that dexamethasone increases erythroid pro-
liferation and differentiation in cells with normal and decreased
levels of RPS19, we investigated whether dexamethasone acts by
increasing expression of the RPS19 gene, either relative to or
coordinately with the expression of genes encoding other ribo-
somal proteins. In addition, we analyzed the effects of 2 other
established or potential DBA therapies: IL-3, which increases red
blood cell production in 15% of patients,22-24 and SCF, which for
many patients normalizes erythroid colony formation in vitro.25-27
Epo was included in all culture conditions because patients with
DBA uniformly have elevated levels of Epo, and dexamethasone
improves the expansion and differentiation of erythroid progenitor
cells from DBApatients in the context of Epo stimulation.14
Primary cells expressing RPS19 shRNAs exhibited a severe
proliferation defect. In order to focus on the effects of various
therapies for DBA, independent of the effects of compromised
proliferation,nonspeciﬁceffectsofshRNAexpression,andpuromy-
cin exposure, we analyzed the effects of the various treatments on
normal human CD34 cells. Cells were cultured with and without
dexamethasone in the presence of Epo alone, Epo plus IL-3, or Epo
plus SCF (Figure 5A). Gene expression was analyzed after 0, 18,
and 48 hours of culture usingAffymetrix U133Amicroarrays.
Expression of RPS19 was not inﬂuenced by dexamethasone,
IL-3, or SCF (Figure 5B-C). The ribosomal protein genes were
Figure 2. Erythroid differentiation is inhibited in human CD34
cells expressing RPS19 shRNAs. In panel A, mean glycophorin A
(Gly-A) expression, assayed by ﬂow cytometry, is shown as a
percentage of the luciferase (luc) shRNA control (mean and SEM). In
panel B, mean CD11b expression is displayed as a percentage of the
control. Methylcellulose colony assays were performed with cells
expressing control or RPS19 shRNAs.The number of BFU-E colonies
is presented in panel C, and the number of CFU-GM colonies is
presented in panel D (mean [SEM]). *P  .001 by 2-tailed Student t
test; **P  .05.
Figure 3. RPS19 shRNAs inhibit cellular proliferation. CD34 cells cultured in
erythroid differentiation medium (A), TF-1 cells (B), HELcells (C), K562 cells (D), and
293 cells (E) were infected with control (luc) or RPS19 shRNAs and selected with
puromycin. Cells were counted by hematocytometer and replated at a constant
density.
Figure 4. Dexamethasone promotes erythroid differentiation in cells express-
ing control and RPS19 shRNAs. (A) Human CD34 cells expressing control (luc) or
RPS19 shRNAs were grown in the presence or absence of dexamethasone (dex),
and mean Gly-A expression was measured by ﬂow cytometry. Fold induction by
dexamethasone is shown as the mean and SEM. (B) Human CD34 cells expressing
control and RP19 shRNAs were grown with or without dexamethasone for 3 days and
then plated on methylcellulose. The number of BFU-E colonies is shown as the mean
and SEM. (C) CFU-GM colonies from the same cultures as panel B are shown as the
mean and SEM. (D) HEL cells expressing the control (luc) or RPS19-R1 shRNA
cultured in the presence (–) or absence (—) of dexamethasone were counted by
hematocytometer and replated at a constant density.
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expression of these genes did not vary across experimental
conditions. Using real-time RT-PCR, we conﬁrmed that RPS19
expression is not altered in HEL cells treated with dexamethasone
or IL-3 for 8 or 24 hours (Figure 5D). Finally, dexamethasone does
not alter RPS19 expression in CD34 cells expressing RPS19
shRNAs, increasing RPS19 expression by only 4% and 11% in
cells expressing RPS19-R1 and RPS19-R2 shRNAs, respectively,
as assessed by real-time RT-PCR.
These experiments indicate that dexamethasone does not in-
crease RPS19 expression. In fact, consistent with previous studies
in murine erythroblast differentiation,28 RPS19 expression de-
creased in human hematopoietic progenitor cells during the course
of erythroid differentiation in vitro (Figure 6). Furthermore, the
expression of RPS19 was tightly coordinated with other ribosomal
proteins. Using the Pearson correlation to rank the 22 284 probe
sets on the U133A microarrays in order of the similarity in their
expression proﬁle across samples, the nearest neighbors of RPS19
were comprised almost entirely of ribosomal proteins and other
proteins involved in translation.At a transcriptional level, RPS19 is
not erythroid speciﬁc in its overall expression or in its expression
relativetoothergenesencodingribosomalproteins.Tightcoregula-
tion with other ribosomal proteins illustrates the primary role of
RPS19 as a ribosomal protein and the need for precise stoichiome-
try in the assembly of ribosomes.
In contrast, the nearest neighbors of Gly-A are coordinately
up-regulated during erythroid differentiation in the same samples
(Figure 6). The nearest neighbors of Gly-A are genes encoding
erythroid-speciﬁcproteins,includingbloodgroupantigens,compo-
nents of the erythrocyte membrane skeleton, and enzymes involved
in heme biosynthesis. The nearest neighbors of Gly-A do not
include any ribosomal protein genes, and the nearest neighbors of
RPS19 do not include any known erythroid-speciﬁc genes.
Taken together, these experiments indicate that the enhance-
ment of erythropoiesis by glucocorticoids is independent of
RPS19. While dexamethasone rescues erythroid differentiation in
RPS19-deﬁcient cells, the induction of erythropoiesis is indepen-
dent of RPS19 levels. Dexamethasone, IL-3, and SCF do not alter
the expression of RPS19 in hematopoietic progenitor cells. More-
over, while dexamethasone increases erythroid differentiation,
RPS19 expression declines during erythroid differentiation.
Molecular targets of dexamethasone
Erythropoiesis has been studied extensively, and key regulatory
genes have been characterized.29 Dexamethasone did not increase
expression of key erythroid regulators (Figure 7A) including
GATA-1, nuclear factor–erythroid 2 (NF-E2), erythroid Kruppel-
like factor (EKLF), and the erythropoietin receptor (EPO-R).
Genes activated in terminal erythroid differentiation, including
globin genes, were down-regulated in cells treated with dexameth-
asonefor18or48hours.Incontrast,genesexpressedinhematopoi-
etic progenitor cells, including c-kit,AML-1, SCL, and MLL, were
up-regulated by dexamethasone. These changes were more pro-
nounced at 48 hours, indicating that these changes may not be
direct targets of dexamethasone.
In order to identify direct targets of dexamethasone, we
examined global patterns of gene expression at the 18-hour time
point. Dexamethasone engages the glucocorticoid receptor, a
transcription factor, and would therefore be expected to activate a
set of genes independent of the signaling cascades induced by
Figure 5. DBA therapies do not regulate the expression of RPS19 or ribosomal genes. As illustrated in panelA, CD34 cells were treated with Epo plus combinations of
dexamethasone (dex), IL-3, and SCF, and gene expression was analyzed using oligonucleotide microarrays. In panels B and C, RPS19 expression and the mean expression of
all ribosomal genes in CD34 cells were assessed by microarrays. Gene expression for each treatment condition and time point is shown relative to gene expression in cells
exposed only to Epo. In panel D, RPS19 expression was evaluated by real-time RT-PCR in HEL cells treated with dexamethasone or IL-3. RPS19 expression is depicted
relative to untreated cells (mean and SEM).
Figure 6. RPS19 is down-regulated during erythroid differentiation. Rows
correspond to the expression of individual genes. The 50 nearest neighbors of
RPS19 (left) and Gly-A(right) are ranked by Pearson correlation. Columns represent
independent microarray experiments of primary CD34 cells undergoing erythroid
differentiation in vitro stimulated by Epo and SCF. The dark red color indicates the
highest gene expression, while the deep blue color reﬂects lowest gene expression.
The nearest neighbors of RPS19 and Gly-A are listed in Tables S3 and S4,
respectively.
.
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cantly in cells exposed to dexamethasone (P  .05 by permutation
testing) across cytokine conditions (Figure 7B).
Many of the genes induced by dexamethasone are known to be
expressed highly in immature hematopoietic progenitor cells or
early erythroid precursors. For example, FLT3 is expressed highly
in hematopoietic stem cells and itself promotes the proliferation of
hematopoietic stem cells.30 Promyelocytic leukemia zinc ﬁnger
(PLZF, ZNF145) is a transcriptional repressor that is expressed at
high levels in hematopoietic progenitor cells, blocks hematopoietic
differentiation by silencing target genes, and forms part of the
PLZF/RARA fusion gene in some patients with acute promyelo-
cytic leukemia.31 Carbonic anhydrase 1 (CA1)32 and gelsolin
(GSN)33 are both known to be expressed at high levels in erythroid
progenitor cells.
The genes most powerfully down-regulated by dexamethasone
include some of the most speciﬁc markers of the lymphocyte,
megakaryocyte, granulocyte, macrophage, and eosinophil lineages.
Expression of 2 genes critical for lymphocyte development, OCT
binding factor 1 (POU2AF1) and terminal deoxynucleotidyltrans-
ferase (DNTT), are decreased by dexamethasone. Expression of
P-selectin (SELP), a component of platelet granules and a marker
of megakaryocytes; eosinophil cationic protein (ECP, RNASE2), a
component of eosinophil granules and a marker of eosinophils; and
the Fc-component of immunoglobulin E (IgE, FCER1A), a marker
of mast cells, are all decreased by dexamethasone. Major histocom-
patibility antigen (MHC) class II genes were down-regulated.
Dexamethasone decreases expression of 3 cytokine genes, interleu-
kin-1 beta (IL-1B), lymphotoxin-beta (LTB), and macrophage
inﬂammatory protein-1-alpha (MIP-1, CC chemokine ligand 3
[CCL3]), all of which are active in myeloid lineage cells.
Discussion
Mutations in the RPS19 gene have been identiﬁed in patients with
DBA, but the role of these mutations in the pathophysiology of
DBA has not been determined. We demonstrate, using retrovirally
expressed shRNAs in cultured human CD34 cells, that decreased
levels of RPS19 are sufﬁcient to cause a severe defect in the
differentiation and proliferation of erythroid progenitor cells.
Glucocorticoids are an effective therapy for patients with DBA,
but the mechanisms of action for dexamethasone and other DBA
therapies are unknown. Dexamethasone increased erythroid differ-
entiation in RPS19-deﬁcient cells in vitro, but the effects of
dexamethasone were independent of RPS19 levels. Furthermore,
dexamethasone did not alter expression of the RPS19 gene or the
genes encoding other ribosomal proteins.
We identiﬁed a set of genes that may be key mediators of the
effects of dexamethasone. FLT3 is a tyrosine kinase that promotes
the proliferation of hematopoietic stem cells,30 PLZF is a transcrip-
tional repressor that blocks hematopoietic differentiation,31 and
Mip-1 is a cytokine that blocks proliferation of hematopoietic
stem cells.34 Induction of PLZF expression by dexamethasone in
smooth muscle cells has been reported previously.35 By increasing
expression of FLT3 and PLZF and decreasing expression of
MIP-1A, dexamethasone may activate proliferation of hematopoi-
etic progenitor cells and delay terminal differentiation. This is
entirely consistent with reported in vitro effects of dexamethasone
on increased erythroid proliferation and maturation delay of
CD34 cells.18 Furthermore, dexamethasone decreased expression
of genes speciﬁc to nonerythroid hematopoietic differentiation
while increasing expression of genes found in immature erythroid
cells. Identiﬁcation of the critical pathways activated by dexameth-
asone may aid in the development of novel therapies with improved
activity for the treatment of DBAwithout the manifold side effects
of glucocorticoids.
Our experiments are consistent with a model of DBA in
which RPS19 deﬁciency decreases the rate of proliferation or
increases the rate of apoptosis of erythroid progenitor cells.
Dexamethasone corrects the defect by increasing proliferation
of erythroid progenitor cells, the cells that are inhibited in DBA.
Our data showing that dexamethasone acts independently of
RPS19 expression are consistent with the efﬁcacy of dexameth-
asone in patients without RPS19 mutations and continued
associated abnormalities found in patients in remission on
steroids such as high erythrocyte adenosine deaminase.
DBA has been termed a pure red blood cell aplasia, yet RPS19
has no clear role in erythropoiesis. In our experiments, expression
of the RPS19 gene was down-regulated during erythropoiesis in
coordination with other ribosomal protein genes. Functionally,
Figure 7. Targets of dexamethasone in CD34 cells were
identiﬁed by oligonucleotide microarrays. (A) The effect of
dexamethasone on the expression of key hematopoietic genes
was analyzed in cells grown in the presence of Epo and SCF. The
fold change in gene expression in response to dexamethasone at
18 and 48 hours of culture is shown for each gene. (B) Rows
correspond to the genes most signiﬁcantly up-regulated and
down-regulated by dexamethasone across cytokine conditions.
Each column is a different microarray experiment of CD34 cells
grown for 18 hours in the presence of the indicated cytokines with
or without dexamethasone. Table S5 contains a list of genes
induced by dexamethasone.
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but also decrease formation of CFU-GM colonies and restrict
proliferation of nonerythroid cells. Independent experiments per-
formed concurrently to this work also demonstrated that RPS19
siRNA expression decreased both erythroid and myeloid colony
formation in primary human hematopoietic cells.36 Nevertheless,
RPS19 may have erythroid-speciﬁc function. The shRNAs used in
our study decrease RPS19 expression to lower levels than in
patients with DBA and may have more general effects due to
disruption of ribosomal activity. In vivo, feedback regulation of the
myeloid lineage may be able to compensate for RPS19 deﬁciency.
The phenotype of DBApatients is not restricted to the erythroid
lineage. Previous studies suggest a defect in stem cells or uncom-
mitted myeloid progenitors.37-39 In fact, many patients with DBA
show progenitor deﬁciencies in vitro that suggest a defect in a
multipotent progenitor. An age-related decline in BFU-Es and
CFU-GMs has been described38,39 as well as a reduction in the
erythroid and myeloid clonogenic output of long-term culture
initiating cells (LTC-ICs).37,40,41 Patients with DBAhave noneryth-
roiddefectsincludinggrowthretardationandcandevelopneutrope-
nia later in life.40,41
Research on DBA has been limited by the lack of an easily
accessible cell culture model of the disease. Partial inactivation of
the RPS19 gene by RNAi creates a model of the disease that can be
used to elucidate the mechanisms of RPS19 deﬁciency further and
to test novel therapies for DBA. Targeted inactivation of other
genes by RNAi in human hematopoietic progenitor cells can be
used to test the function of other DBA candidate genes and to
model other disorders of hematopoietic differentiation caused by
decreased expression of a critical gene.
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